Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial

https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00488-1/fulltext?dgcid=hubspot_update_feature_updatealerts_eclinm&utm_campaign=update-eclinm&utm_medium=email&_hsmi=288654180&_hsenc=p2ANqtz-_Til1ZHnjCMD4sXK2qxE6x2vvOLZQtKEs6k8jdAavq3U5VdoVoxp2G9aYbwzdge1GdleYDw6oEWX5HLRzHRkGcjc3NwQ&utm_content=288192507&utm_source=hs_email